OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Copeland on the Importance of Germline Testing in Ovarian Cancer

March 26th 2020

Larry J. Copeland, MD, discusses the importance of germline testing in ovarian cancer.

Dr. Mesa on Investigative Therapies in Myelofibrosis

March 26th 2020

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Dr. Kremyanskaya on MANIFEST Trial With CPI-0610 in Myelofibrosis

March 26th 2020

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Dr. Feldman on the Shortcomings of PET Scan in Hodgkin Lymphoma

March 26th 2020

Tatyana Feldman, MD, discusses the shortcomings of PET scan in Hodgkin lymphoma.

Dr. Steensma on the Utility of Venetoclax in MDS

March 26th 2020

David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.

Dr. Altomare on the Management of ITP

March 26th 2020

Ivy P. Altomare, MD, discusses the management of patients with immune thrombocytopenia purpura.

Dr. Chagpar on Limiting the Spread of COVID-19

March 25th 2020

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Dr. Le on the Need for Aggressive Treatment Interventions in Oligometastatic CRC

March 25th 2020

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Dr. Raghav on Treatment Options in Newly Diagnosed mCRC

March 25th 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC

March 25th 2020

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer

March 25th 2020

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

March 25th 2020

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Dr. Abdul Hay on Evaluation of Transplant Eligibility in ALL

March 25th 2020

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

March 25th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

March 25th 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

Dr. Kahl on Treatment Strategies for Indolent Lymphoma

March 25th 2020

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias

March 25th 2020

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Dr. Grossbard on the Role of MRD in Follicular Lymphoma

March 24th 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Dr. Cutler on Optimizing Treatment for Acute and Chronic GVHD

March 24th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Dr. Westin on Treatment Challenges in Large Cell Lymphoma

March 24th 2020

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.